CD4 and neoplasm: B cells, which are important players in the cross-talk of the innate and adaptive immunity [37], recovered at V5 and increased during nivolumab treatment, concomitant with the number of CD3+/CD8+, CD3+/CD4+, and CD3+/CD56+ T cells that might also contribute to protective anti-tumor immunity.